Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 10, Issue 9, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-10
DOI
10.1038/s41419-019-1875-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
- (2019) Christiane Margue et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations
- (2018) Hidejiro Torigoe et al. CANCER SCIENCE
- MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients
- (2018) Michael Constantin Kirchberger et al. EUROPEAN JOURNAL OF CANCER
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
- (2018) Lucia Demkova et al. Molecular Cancer
- Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma
- (2018) Melanie Werner-Klein et al. Nature Communications
- Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
- (2018) Ewelina Dratkiewicz et al. Oncotarget
- WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy
- (2018) Lillian Sun et al. OncoImmunology
- Resistance mechanisms to genetic suppression of mutant NRAS in melanoma
- (2017) James P. Robinson et al. MELANOMA RESEARCH
- Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
- (2017) Alireza Azimi et al. Cell Death & Disease
- Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo
- (2017) Xiangxiang Hu et al. Scientific Reports
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Chk1 and Wee1 control genotoxic-stress induced G2–M arrest in melanoma cells
- (2015) Julio Vera et al. CELLULAR SIGNALLING
- Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines
- (2015) Simone Gusenbauer et al. Molecular Cancer
- RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression
- (2015) Karine A. Cohen-Solal et al. Molecular Cancer
- Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines
- (2015) Liangkun You et al. Oncotarget
- IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide
- (2015) Roger Ramcharan et al. Oncotarget
- Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
- (2014) Gillian M. Keating DRUGS
- Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
- (2014) E Weisberg et al. LEUKEMIA
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- ERBB3 is required for metastasis formation of melanoma cells
- (2014) S Tiwary et al. Oncogenesis
- CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
- (2013) L. Chaudhuri et al. HAEMATOLOGICA
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
- (2013) Gang Chen et al. PLoS One
- Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
- (2013) Shigeki Nanjo et al. PLoS One
- Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2
- (2013) M. Acunzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
- (2013) C. Posch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy
- (2012) Gry Irene Magnussen et al. PLoS One
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Role of TGF-β in Melanoma
- (2011) A. Busse et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
- (2009) Michalis V Karamouzis et al. LANCET ONCOLOGY
- ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
- (2009) Emelie A. Djerf et al. MELANOMA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started